DexCom, Inc. Dividend History (DXCM)
DexCom, Inc. does not pay dividends currently 😔
They might in the future, check back soon!
About DexCom, Inc.
DexCom, Inc. is a prominent company specializing in the development, manufacture, and distribution of continuous glucose monitoring (CGM) systems for diabetes management. Founded in 1999 by Alec C. B. Radford, the company is headquartered in San Diego, California. DexCom's advanced technology helps individuals with diabetes keep track of their blood glucose levels in real-time without the need for traditional fingersticks, offering valuable insights for better glycemic control. The G-Series CGM systems, including the popular Dexcom G6, are among their flagship products, praised for their reliability, accuracy, and ease of use. The company's innovation in the health tech space has significantly improved quality of life for those with diabetes. DexCom has experienced strong financial growth, underpinned by increasing adoption of its technology. In 2022, the company reported revenues of approximately $2.91 billion, reflecting its robust market presence. DexCom continues to expand globally, aiming to transform diabetes care with cutting-edge solutions.
Abbott Laboratories
AMN Healthcare Services, Inc.
HealthEquity, Inc.
Insulet Corporation
Integer Holdings Corporation
DexCom, a leader in continuous glucose monitoring (CGM) systems, faces some near-term challenges but has strong long-term growth potential. The company can expand its market by entering new territories, increasing third-party coverage, and developing new devices. Despite a recent drop in valuation, DexCom's dominance in the CGM market and strong financial results make it an attractive investment opportunity for patient investors.
The Motley Fool · Published on Mon Dec 02 2024
The article discusses two healthcare companies, DexCom and Intuitive Surgical, that are well-positioned to deliver strong returns in the next decade. DexCom is a leader in continuous glucose monitoring systems, while Intuitive Surgical dominates the robotic-assisted surgery market with its da Vinci system.
The Motley Fool · Published on Thu Nov 28 2024
The article discusses the worst-performing stocks in the Nasdaq-100 index so far in 2022, emphasizing that investors should not abandon long-term investments due to short-term slumps. It suggests considering the underlying reasons for the price declines and maintaining a long-term perspective.
The Motley Fool · Published on Tue Nov 26 2024